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B Cells and Immunological Tolerance
Nataly Manjarrez-Ordun˜o1, Taˆm D. Qua´ch1 and In˜aki Sanz1
Work from multiple groups continues to provide additional evidence for the powerful and highly diverse roles,
both protective and pathogenic, that B cells play in autoimmune diseases. Similarly, it has become abundantly
clear that antibody-independent functions may account for the opposing influences that B cells exercise over
other arms of the immune response and ultimately over autoimmunity itself. Finally, it is becoming apparent
that the clinical impact of B-cell depletion therapy may be, to a large extent, determined by the functional
balance between different B-cell subsets that may be generated by this therapeutic intervention. In this review,
we postulate that our perspective of B-cell tolerance and our experimental approach to its understanding are
fundamentally changed by this view of B cells. Accordingly, we first discuss current knowledge of B-cell
tolerance conventionally defined as the censoring of autoantibody-producing B cells (with an emphasis on
human B cells). Therefore, we discuss a different model that contemplates B cells not only as targets of
tolerance but also as mediators of tolerance. This model is based on the notion that the onset of clinical
autoimmune disease may require a B-cell gain-of-pathogenic function (or a B-cell loss-of-regulatory-function)
and that accordingly, disease remission may depend on the restoration of the physiological balance between
B-cell pathogenic and protective functions.
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INTRODUCTION
It has been amply demonstrated that B
cells have critical initiating and/or
amplifying pathogenic roles in a wide
variety of autoimmune diseases
through both antibody-dependent and
-independent mechanisms (Chan et al.,
1999; Martin and Chan, 2006; Sanz
et al., 2007). A large body of experi-
mental evidence to that effect has been
recently validated by the observed
beneficial effect of B-cell depletion
therapies in multiple autoimmune dis-
eases both in humans and mice (Ed-
wards et al., 2004; Looney et al., 2004;
Hasegawa et al., 2006; Ahuja et al.,
2007; Hu et al., 2007; Sanz et al.,
2007; Xiu et al., 2008). Of note,
conditions that improve with B-cell
depletion therapy include both diseases
typically considered of B-cell origin
(systemic lupus erythematosus (SLE),
idiopathic autoimmune thrombocyto-
penia, dermatomyositis, and autoim-
mune blistering diseases) as well as
diseases for which B cells are not
viewed as prime movers (including
rheumatoid arthritis, multiple sclerosis,
and type 1 diabetes) (Edwards et al.,
2004; Looney et al., 2004; Todd, 2005;
Ahmed et al., 2006; Schmidt et al.,
2006; Hu et al., 2007; Hauser et al.,
2008; Xiu et al., 2008). These observa-
tions strongly suggest that the patho-
genic functions of B cells must be
undoubtedly diverse and, although it
is likely that they may also include the
action of nonautoreactive B cells, it
seems unquestionable that autoreactive
B cells need to be censored to avoid or
ameliorate autoimmune diseases. Gi-
ven that B cells with at least some
degree of autoreactivity are extremely
common in the primary, pre-antigenic
repertoire of mice and humans, it is
apparent that effective censoring me-
chanisms must be operative during
early B-cell development (central
tolerance) (Guilbert et al., 1982;
McHeyzer-Williams and Nossal, 1988;
Souroujon et al., 1988; Wardemann
et al., 2003). Moreover, regulation must
also be enforced at later stages of B-cell
differentiation to censor autoreactive
cells that either escape earlier check-
points or are generated anew from
mature nonautoreactive B cells (periph-
eral tolerance). Indeed, multiple check-
points enforced by different mechanisms
have been defined throughout B-cell
development (from immature B cells to
preplasma cells) mostly in animal mod-
els (Goodnow, 2001; Goodnow et al.,
2005, 2007; Culton et al., 2006;
Shlomchik, 2008) (see Table 1 for
definition of these subsets).
Although our knowledge of the
mechanisms of human B-cell tolerance
is continuously expanding (Pugh-Ber-
nard et al., 2001; Wardemann et al.,
2003, 2004; Tsuiji et al., 2006;
Tiller et al., 2007; Wardemann and
PERSPECTIVE
278 Journal of Investigative Dermatology (2009), Volume 129 & 2009 The Society for Investigative Dermatology
Received 27 March 2008; revised 29 May 2008; accepted 10 June 2008
1Division of Allergy, Immunology and Rheumatology, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New
York, USA
Correspondence: Dr In˜aki Sanz, Division of Allergy, Immunology and Rheumatology, Department of Medicine, University of Rochester, 601 Elmwood Avenue,
Box 695, Rochester, New York 14642, USA. E-mail: Ignacio_Sanz@urmc.rochester.edu
Abbreviations: BCR, B-cell receptor; GC, germinal center; IL, interleukin; MZ, marginal zone; SLE, systemic lupus erythematosus; T2-MZP, transitional 2/MZ
precursors
Nussenzweig, 2007) several critical
questions remain to be addressed. They
include: (1) the precise definition of the
censoring mechanisms that enforce
physiological tolerance at different
checkpoints during B-cell develop-
ment; (2) the mechanisms of break-
down of physiological tolerance in
autoimmunity (bearing in mind that
they may differ from disease to disease
and that that even within a single
disease they may be different for
separate autoantigens); (3) the relative
contribution to immunopathogenesis of
antigen-specific (autoreactive) versus
antigen nonspecific (nonautoreactive)
B cells; and (4) the critical and largely
unexplored question of whether the
main objective of B-cell tolerance is
merely to prevent the accumulation of
autoantibody-secreting B cells or to
block autoreactive B cells from becom-
ing pathogenic by antibody-independent
mechanisms (gain-of-function model).
Here we try and put what is known
about human B-cell tolerance and its
breakdown in autoimmune diseases in
the context of these models. In doing so,
we discuss B cells as both targets and
mediators of immunological tolerance.
B cells as targets of immunological
tolerance
In animal models, B-cell tolerance is
established through multiple mechanisms
both intrinsic and extrinsic to the
autoreactive B cells in question
(Figure 1). These mechanisms have
been elegantly discussed in detail in
several recent reviews (Goodnow et al.,
2005, 2007; Kumar and Mohan, 2008;
Shlomchik, 2008). Their relative parti-
cipation and effectiveness in censoring
autoreactive cells depend on a combi-
nation of self-antigen availability, its
avidity and ability to cross-link the B-
cell receptor (BCR) and to engage
innate immune receptors (TLR), the
abundance of survival factors (in parti-
cular BAFF/B-cell activating factor) and
the ability of the autoreactive B cell to
compete for them and the balance
between activating Th cells and inhibi-
tory Treg cells. In addition, autoreac-
tive B cells can also be inhibited by
macrophages and dendritic cells at
least in part through the production of
IL-6 and CD40L (Kilmon et al., 2005,
2007). Ultimately, the combination of
these factors determines whether an
immature autoreactive B cell is cen-
sored by one or more of the following
mechanisms: (1) maturational arrest
and follicular exclusion leading to
premature death and clonal deletion
(Goodnow, 1988; Mandik-Nayak et al.,
1997); (2) receptor editing (eliminating
the original autoreactivity by the sec-
ondary rearrangement of a new light
chain) (Nemazee and Weigert, 2000);
(3) receptor dilution because of the co-
expression of two light chains as a
result of allelic inclusion. This process
may decrease the density of surface
autoantibody expression partly or com-
pletely, in the latter case owing to
intracellular sequestration of the auto-
reactive receptor rather than preferen-
tial pairing of the light-chain editor
(Gay et al., 1993; Liu et al., 2005); or
(4) anergy (defined as the inability of
chronically stimulated autoreactive
cells to respond to further antigenic
stimulation and spanning a wide spec-
trum of other phenotypic and func-
tional characteristics that vary with the
experimental system used to study
anergy) (Goodnow, 1988; Noorchashm
et al., 1999; Rui et al., 2003; Liu and
Manser, 2005; Acevedo-Suarez et al.,
2006; Cambier et al., 2007; Shlomchik,
2008). Of note, transgenic autoreactive
anergic B cells have been typically
considered maturationally arrested on
the basis of a transitional phenotype.
However, important recent data con-
tributed by Merrell et al. (2006) have
demonstrated that chronic BCR stimu-
lation may also induce an anergic late
transitional (T3) phenotype in mature,
nonself reactive wild-type cells. These
data suggest that autoreactive B cells
may progress to the mature compart-
ment yet regress back into the T3
compartment upon stimulation by
self-antigen. This observation raises
important questions regarding the lo-
cale and type of stimulation that would
induce anergy in mature autoreactive
cells that escaped that fate at an earlier
stage of differentiation.
Of interest, anergy can also contri-
bute to censoring mature autoreactive
B cells in some transgenic systems
(Benschop et al., 2001; Acevedo-Suar-
ez et al., 2006). Autoreactivity at the
mature stage can also be enforced by
additional mechanisms during antigen-
induced T cell-dependent germinal
center (GC) reactions (Goodnow
et al., 2005, 2007; Shlomchik, 2008).
GC mechanisms of tolerance include:
cell death induced either by FasL on
activated T cells or by self-antigen-
induced BCR signaling; prevention of
autoreactive plasma cell differentiation
by BCR signaling; lack of productive
interaction with follicular T helper
Table 1. Markers that define B-cell subpopulations
B-cell subset
Transitional CD27+ memory
Marker Immature T1 T2 T3 Naive Unswitched Switched Plasma cells
IgD  + ++ ++ ++ +  
CD27      + + High
CD19 + + + + + + + Low
CD10 + + +/ /+    +/
CD24 +++ +++ ++ + + ++ ++ 
IgM ++ +++ ++ + + +  
R123 + + + Int  + + +
CD38 +++ +++ ++ + + Low Low High
Modified from Sanz et al. (2008). In addition to these subsets, germinal center B cells are
characterized as IgD, CD38++, CD10+ and generally CD27+ (Cappione et al., 2005). Spleen
marginal zone B cells are typically CD27+, CD21++, CD23+/, CD1c+, and IgD (although an
outer marginal zone population is also observed in human spleen). Peripheral blood unswitched
CD27+ memory B cells may represent a recirculating marginal zone population also bearing the
CD1c marker (Weller et al., 2004). Finally, long-lived plasma cells found in human bone marrow as
well as spleen and tonsils express CD138 in addition to high levels of CD38 (Medina et al., 2002).
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cells; and attenuation of autoreactivity
by BCR modification either through
somatic hypermutation or receptor
revision. Finally, additional mechan-
isms of tolerance may also be operative
during the late stages of B-cell differ-
entiation and antibody production as
reviewed elsewhere (Goodnow et al.,
2007). Late mechanisms and the spe-
cific locales where they may take place
are less well understood although
checkpoints for anti-Smith preplasma
cells (CD138þ nonsecreting plasma
cells) are operative in the bone marrow
and in the spleen of normal mice)
(Culton et al., 2006).
Essentially, all the previous mechan-
isms amount to negative selection of
autoreactive B cells. It should be noted
however that positive selection may
shift cells into the B1a and marginal
zone (MZ) compartments (Cancro and
Kearney, 2004). At least in the mouse,
both B1 cells (defined as IgMhigh,
IgDlow, CD5þ ) and MZ B cells (de-
fined as IgMhigh, CD21high, CD23low,
IgDlow) represent innate-like B-cell
populations that may contribute to the
regulation of autoreactive B cells
through a compartmentalization pro-
cess (in the peritoneal and pleural
cavities for B1 cells and in the splenic
MZ for MZ cells) that prevents them
from either encountering antigen and/
or undergoing further maturation and
diversification (in GC for instance)
(Murakami et al., 1992; Hayakawa
et al., 1999; Martin and Kearney,
2000; Li et al., 2002). Of particular
interest in this context, partially auto-
reactive B cells as a result of light-chain
allelic inclusion have been shown to
accumulate in the MZ (Li et al., 2002).
Of note however, in other models,
positive selection or expansion of
autoreactive MZ B cells can also
induce clinical autoimmunity (Grimaldi
et al., 2001).
–
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Figure 1. Checkpoints and mechanisms of B-cell tolerance with emphasis on human models. Schematic representation of the multiple checkpoints,
mechanisms, and determinants of tolerance during early and late B-cell development. By and large, the information summarized is derived from transgenic
mouse models. The two main human experimental models of B-cell tolerance are depicted superimposed on the figure (checkpoints for 9G4 cells are shown
with blue signs and ANA reactivity is shown in red; þ , positive selection; , negative selection). This figure ignores the B1 compartment as no clear and
unequivocal definition or even definitive proof of its existence is available for humans. The model also tries to incorporate existing questions regarding the
identity of human recirculating MZ cells and the nature of the MZ precursor population (either transitional or follicular naive B cells). For the purpose of this
review, peripheral blood IgDþ (unswitched) CD27þ memory cells are considered a circulating MZ equivalent and represent the IgMþ memory population
studied in terms of ANA autoreactivity. Such autoreactivity has been shown to decrease significantly when either the transitional or naive follicular compartment
is compared with unswitched memory cells. Accordingly, a red negative selection sign has been assigned to these potential checkpoints. T, transitional cells;
PC, plasma cells; FTH, follicular T helper cells.
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Finally, on other animal models, the
activation of some types of autoreactive
B cells (including rheumatoid factor,
anti-DNA, and anti-La B cells) appears
to be prevented by clonal ignorance or
antigenic indifference (Hannum et al.,
1996; Koenig-Marrony et al., 2001;
Aplin et al., 2003; Liu and Manser,
2005). These mechanisms however
permit the maturation and accumula-
tion of such autoreactive cells and
therefore, the censoring achieved is
rather tenuous. Indeed, the danger of
the persistence of ignorant cells is
illustrated by the AM14 transgenic
model in which autoreactive rheuma-
toid factor B cells normally develop in
the follicular and MZ compartments
without generating autoantibodies
in normal mice, but not in an auto-
immune background (Wang and
Shlomchik, 1999).
Despite tremendous progress in our
understanding of B-cell tolerance,
much less is known about the specific
defects in different checkpoints under-
lying tolerance breakdown in autoim-
mune diseases. In particular, as
discussed elsewhere, the importance
of breakdown of mechanisms of central
tolerance is unclear in many animal
systems (Shlomchik, 2008). These as-
pects are discussed for human disease
below. An in-depth discussion of other
experimental systems is outside the
scope of this review and can be found
in recent publications by other authors
(Goodnow et al., 2005; Shlomchik,
2008).
Mechanisms of B-cell tolerance in
humans
For obvious reasons, experimental ap-
proaches to the study of B-cell toler-
ance are more limited in humans than
in the mouse. Essentially, two major
experimental systems have been em-
ployed to assess the frequency of
autoreactive B cells in different devel-
opmental compartments and to identify
the checkpoints and mechanisms that
limit their access to compartments that
presumably hold the most pathogenic
potential (that is, the long-lived immu-
noglobulin G (IgG) memory and plas-
ma cell compartments) (Pugh-Bernard
et al., 2001; Wardemann and Nussenz-
weig, 2007) (Figures 2 and 3). Our
laboratory has concentrated on the
study of a particular subset of auto-
reactive human B cells identified by the
expression of an idiotype recognized
by the 9G4 rat anti-human Ig mono-
clonal antibody (for convenience, we
designate these cells as 9G4þ cells
and the antibodies they produce as
9G4 antibodies) (Pugh-Bernard et al.,
2001; Cappione et al., 2005). This
system has the advantage that cells
can be identified using flow cytometry,
thereby allowing the analysis of mil-
lions of cells that are homogeneous at
least for the expression of this auto-
reactivity-associated marker. More-
over, in healthy subjects, IgM 9G4
antibodies are universally autoreactive
at a minimum against the N-acetyllac-
tosamine residues expressed by the
blood group Ii antigens and many other
self-glycoproteins including CD45/
B220. The latter autoreactivity is re-
sponsible for the ability of 9G4 anti-
bodies to bind to B cells and may
contribute to B-cell lymphopenia in
active SLE (Bhat et al., 1997; Pugh-
Bernard et al., 2001; Cappione et al.,
2004). At least some IgM 9G4 anti-
bodies are also able to recognize other
self antigens such as DNA, ganglio-
sides, IgG (rheumatoid factor activity),
and neutrophil cytoplasmic antigens
activity and may in some cases cross-
react with the lipid A moiety of
lipopolysaccharide (Spellerberg et al.,
1995; Longhurst et al., 1996; Thorpe
et al., 1998; Bhat et al., 2000). The
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Figure 2. A broader view of B-cell tolerance. Additional late checkpoints. Conventional late
checkpoints are viewed as preventing the generation of autoreactive long-lived memory B cells and
plasma cells to avoid autoantibody accumulation. Additional checkpoint could be envisioned that block
the generation of autoreactive effector B cells (BE) from either newly recruited GC cells or preexisting
central memory cells (BCM) (Harris et al., 2000; Sanz et al., 2008). Such hypothetical checkpoints are
indicated in this figure (whether effector B cells may represent a distinct subset of memory B cells and
whether they can also generate plasma cells remains to be elucidated).
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Figure 3. The dual nature of B cells in autoimmunity. B cells are endowed with a Janus-like quality that
enables them to perform functions that either promote or suppress autoimmunity. Although division of
labor is likely to exist between different B-cell populations, it is also possible that the function of a given
B-cell subset could be induced or modulated by the dominant cytokine environment characteristic of
different autoimmune diseases.
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combination of these properties to-
gether with the high frequency of 9G4
B cells in the primary repertoire of
healthy subjects (5–10% of all imma-
ture and naive B cells) and the absolute
absence of VH4-34 genetic polymorph-
ism in the human population create a
situation as close as one can get in
humans to experimental transgenic
systems where homogeneous autoreac-
tive B cells have to coexist with
competing nonautoreactive B cells. Of
significant importance, 9G4-associated
autoreactivity is owed to the utilization
by these B cells and antibodies of
heavy chains encoded by VH4-34
genes that preserve the germ-line-en-
coded expression of the 9G4 idiotype
(Potter et al., 1993). Therefore, one
should bear in mind when trying to
understand the regulation of the auto-
reactivity of 9G4 B cells that although
9G4þ cells may be universally auto-
reactive that may not be the case for all
VH4-34þ B cells as somatic hypermu-
tation may abolish both the expression
of the 9G4 idiotype as well as the
associated autoreactivity.
Taken together, our studies of the
9G4 system have overcome two major
obstacles that traditionally hamper the
understanding of human B-cell toler-
ance: (1) the identification of a popula-
tion of well-defined autoreactive B
cells which are relevant and specific
for a given autoimmune disease (SLE)
and whose frequency is large enough to
permit accurate measurements (Pugh-
Bernard et al., 2001); (2) the analysis of
autoimmune secondary lymphoid tis-
sue in a systematic fashion (Cappione
et al., 2005). As regards disease rele-
vance and specificity, elevated serum
titers of 9G4 IgG antibodies, although
very rare in healthy subjects, are found
in approximately 70% of patients with
active SLE, are highly specific for this
disease where they correlate with dis-
ease activity, and organ involvement
(kidney and central nervous system)
and participate in anti-DNA antibody
responses (including antibodies ob-
tained from kidney eluates) and anti-
Smith responses (Longhurst et al., 1996;
van Vollenhoven et al., 1999; del
Rincon et al., 2000). At a cellular level,
despite the high frequency of 9G4
naive B cells, in healthy subjects 9G4
cells are markedly diminished
(80–90%) in the IgG memory compart-
ment and 9G4þ plasma cells are very
hard to find (Pugh-Bernard et al., 2001;
Cappione et al., 2005). The absence of
9G4þ plasma cell described in our
laboratory using intracellular staining
of magnetically purified CD138þ
plasma cells from healthy bone marrow
and tonsils is indeed striking and
consistent with the virtual absence of
9G4 antibodies in more than 200
multiple myeloma tumors thus far
analyzed by different groups (Rettig
et al., 1996; Pugh-Bernard et al.,
2001; Froyland et al., 2007).
These observations led us to postu-
late that autoreactive 9G4 cells should
be strictly censored in the peripheral
compartment of healthy subjects and
more specifically in the GC as these
functional and anatomical structures
are the primary, albeit not the only,
generators of isotype switched memory
cells and long-lived plasma cells (Wil-
liam et al., 2002; Xu et al., 2007).
Indeed, our analysis of normal tonsil
and spleen specimens demonstrated
that naive 9G4 cells are normally
prevented from establishing GC reac-
tions as demonstrated by the absence of
9G4þ GCs in more than 700 follicles
(from 12 tonsils and 5 spleens) thus far
analyzed in our laboratory. Such strict
censoring appears to be largely accom-
plished in the early phases of the GC
reaction (Pugh-Bernard et al., 2001;
Cappione et al., 2005) (Figure 1). The
actual mechanism(s) responsible for the
censoring remain to be elucidated in
more detail. However, despite the fact
that 9G4 cells do become mature
follicular cells (in contrast to some but
not all mouse models of anergy), these
cells are anergic in their response to
BCR stimulation ex vivo as indicated by
Caþ þ flux analysis. More recent re-
sults using intracellular phospho-flow
cytometry techniques also indicate
BCR hyporesponsiveness in 9G4 cells
(Jenks et al., manuscript in preparation).
Of note, as hen egg lysozyme also
reported for mouse anti-HEL anergic B
cells, healthy 9G4 B cells hypoproliferate
under BCR plus CpG DNA stimulatory
conditions indicating that co-stimulation
through TLR9 fails to overcome their
anergic state (Manjarrez-Ordun˜o et al.,
manuscript in preparation) (Rui et al.,
2003). Finally, we have shown that 9G4
B cells accumulate in substantial num-
bers in the splenic MZ. Although the
actual origin of MZ B cells remain
controversial, there is strong evidence
that at least in part they derive from a
transitional/MZ precursor population
through a developmental pathway se-
parate from follicular cells (Meyer-
Bahlburg et al., 2008). Accordingly,
our observations of the presence of
high frequency of 9G4 B cells within
both the follicular and MZ compart-
ments strongly suggest that immature/
transitional 9G4 B cells may be hetero-
geneous in terms of their autoreactivity
and contain distinct subpopulations
that are differentially selected. Current
investigation in our laboratory is aimed
at the elucidation of the types of
autoreactivity present in early 9G4
cells and their preferential selection
into the follicular and MZ compart-
ments. We are also investigating the
role of receptor editing in this early
selection phase.
As in the mouse, understanding
which and how physiological mechan-
isms of tolerance go awry in human
autoimmune diseases remains a for-
midable challenge. In the 9G4 system,
all the serological observations gener-
ated over almost 15 years by different
groups, strongly indicated that subver-
sion of these mechanisms should occur
in SLE in a disease-specific fashion (van
Vollenhoven et al., 1999; Cappione
et al., 2005). Proving this point re-
quired access to secondary lymphoid
tissue in autoimmune patients. This
limitation was overcome through the
pioneering use of tonsil biopsies for
such purpose (Cappione et al., 2005).
With this approach we have demon-
strated that indeed faulty GC censoring
of 9G4 B cells occurs specifically in
SLE and is not shared by rheumatoid
arthritis patients (Cappione et al.,
2005). Thus, approximately 25% of all
productive GC in SLE tonsils are 9G4þ
as compared to virtually none in
healthy subjects or in RA tonsils. This
defect results in a 10- to 25-fold
expansion of 9G4þ B cells within the
IgG memory compartment of second-
ary lymphoid tissue. Moreover, 9G4
antibodies are expressed in up to
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30% of peripheral blood lymphocyte
plasmablasts in active SLE, which
represents a pronounced contrast with
the remarkable absence of 9G4 plasma
cells in normal subjects (Isenberg et al.,
1993, 1998). Together with previous
demonstrations of the high specificity of
9G4 serum antibodies for SLE (495%
and comparable to anti-ds DNA anti-
bodies) and of the association of serum
9G4 antibody levels with disease
activity and organ involvement in SLE
(Isenberg et al., 1993, 1998; van
Vollenhoven et al., 1999), our results
clearly establish the relevance of study-
ing the fate of 9G4 B cells to assess B-
cell tolerance in SLE. Still, a precise
definition of the actual defects involved
in the breach of 9G4 B-cell tolerance in
SLE remains to be established. Studies
of B-cell signaling, BAFF-mediated sur-
vival, antigen-availability in the GC,
collaboration with follicular T helper
cells, and suppression by Treg cells are
currently underway. Of note, our initial
studies of HIV patients have identified a
subset of patients with serum IgG levels
of 9G4 antibodies comparable to those
previously found only in active SLE.
These observations provide an oppor-
tunity to identify common factors be-
tween the two conditions, such as
potential defects in Treg cell function
that could influence the regulation of
the 9G4-associated autoreactivity.
Another highly informative experi-
mental system has employed single-
cell PCR technology to isolate the
antibodies expressed by B cells and
determine the fate of B cells with
autoreactivity against nuclear antigens
(either global ANA reactivity or anti-
DNA reactivity) both in healthy sub-
jects and in autoimmune patients with
SLE and RA (Wardemann et al., 2003,
2004; Yurasov et al., 2005; Tsuiji et al.,
2006; Tiller et al., 2007). Several
striking findings have been derived
from these studies. First, immature B
cells in the primary bone marrow
repertoire of healthy subjects display a
very high level of autoreactivity
(B75%) and a significant degree of
polyreactivity. Second, several early
checkpoints operative in the bone
marrow as well as peripherally appear
to be effective in healthy subjects as
this initial level of nuclear autoreactiv-
ity diminishes progressively as imma-
ture B cells differentiate into mature
naive B cell (20% autoreactive and 5%
polyreactive) and then into unswitched
IgM memory cells which are essentially
devoid of the autoreactivity and poly-
reactivity (when the antibodies are
expressed as IgG molecules) present
in earlier B cells. In this system, clonal
deletion and possibly receptor editing
appear to account for the censoring
observed at these early checkpoints. Of
great interest, additional work by the
same investigators has demonstrated
that these early censoring checkpoints
seem to malfunction in SLE and RA
patients leading to significantly higher
levels of antinuclear reactivity in the
naive B cells than healthy controls
(Samuels et al., 2005; Yurasov et al.,
2005). Somewhat unexpectedly how-
ever, recent results have shown that the
level and type of nuclear autoreactivity
eliminated in the early checkpoints in
healthy subjects are restored during the
GC reaction by somatic hypermutation
and antigen selection resulting in high
levels of ANA reactivity in the post-GC
IgG memory compartment (Tiller et al.,
2007). These studies raise important
questions. Perhaps most critical is
whether GCs do not effectively censor
pathogenic autoreactivity in humans.
Several explanations could be invoked
to reconcile these findings with the
absence of clinical autoimmunity in
healthy subjects and with the descrip-
tion in mouse models of multiple GC-
based tolerance mechanisms as well as
our own results in the 9G4 system
(Pugh-Bernard et al., 2001; Cappione
et al., 2005; Goodnow et al., 2005).
Thus, it is possible that the low-affinity
autoreactivity detected in the IgG
compartment might not be pathogenic
and consequently there would be no
need for further censoring. Alterna-
tively, the autoreactivity detected could
be pathogenic or at least have the
potential to become pathogenic, but it
would be regulated at later checkpoints
thereby blocking their differentiation
into antibody-producing plasma cells, a
scenario consistent with the description
in mouse models of preplasma cell
autoreactivity checkpoints (Culton
et al., 2006; Goodnow et al., 2007). It
should be noted however that the GCs
are the site of differentiation of long-
lived plasma cells from high-affinity
B cells and therefore, it seems likely
that GCs should be operative in the
implementation of late tolerance check-
points (Smith et al., 2000; Tarlinton,
2008). It could therefore be postulated
that although GCs might allow and/or
promote the generation of autoreactive
memory cells of low affinity, they
would censor the different ion of
high-affinity autoreactive B cells.
A multidimensional view of B-cell
tolerance beyond the censoring of
autoantibody production
Multiple challenges remain to be over-
come to understand and manipulate
B-cell tolerance. It seems indisputable
that effective tolerance mechanisms
should prevent the expansion and
activation of pathogenic autoreactive
B cells. Typically, as previously dis-
cussed in this review, the process of
tolerance is defined as the elimination,
editing or silencing of self-reactive B
cells to ultimately prevent the excessive
production of pathogenic autoanti-
bodies. Hence, by and large, the
investigation of B-cell tolerance deals
with pathogenic B cells defined as
autoantibody-producing B cells, and
conventional readouts of tolerance
and evaluation of tolerogenic check-
points consist of the frequency of
autoreactive B cells and the level of
serum autoantibodies.
It is obvious therefore, that a critical
challenge is to be able to discriminate
pathogenic from merely self-reactive
B cells. Moreover, as the evidence
continues to accumulate for antibody-
independent pathogenic roles in multi-
ple autoimmune diseases, it becomes
essential to understand the mechanisms
and consequences of B-cell tolerance
from a wider angle. Are all autoreactive
B cells created equal? How can we
identify pathogenic B cells? What
determines the pathogenic function(s)
of an autoreactive B cell? How is
this function acquired and can it be
reversed? What’s the relative patho-
genic contribution of antibody-
mediated and antibody-independent
functions? A detailed understanding of
these questions would lead to better
diagnostic, prognostic, and therapeutic
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tools for the prevention of autoimmu-
nity in high-risk subjects and for the
management of disease in autoimmune
patients.
Hence, it should be useful to discuss
a more encompassing model which
postulates that at least in some auto-
immune conditions or in some of their
phases (such as pre-autoimmunity or
during spontaneous or treatment-in-
duced disease remission), the presence
of autoantibody-producing cells is not
sufficient for B cell-mediated autoim-
munity (Figure 2). The need for this
model is powerfully illustrated by the
consistent observation that even iso-
type-switched autoantibodies may pre-
cede disease onset by several years (as
in SLE and type 1 diabetes), thereby
suggesting that additional pathogenic
functions are required for disease in-
duction (Bingley et al., 1997; Arbuckle
et al., 2003). Such a gain-of-pathogenic
function model would require that
autoreactive B cells acquire other
pathogenic properties, such as the
ability to activate pathogenic T cells,
the production of proinflammatory
cytokines, and/or the promotion of
tertiary lymphoid tissue in target organs
(Takemura et al., 2001; Vinuesa and
Cook, 2001; Aloisi and Pujol-Borrell,
2006). Although these additional func-
tions may also be B-cell extrinsic and
also include the generation of addi-
tional autoantibody species and the
modification of preexisting ones (such
as modified glycosylation leading to
increased pathogenic activity) (Kaneko
et al., 2006; Collin et al., 2008), the
therapeutic benefit of B-cell depletion
and, at least in several diseases, the
antibody-independent benefit of this
intervention, strongly point to B cells
as critical recipients of gain-of-patho-
genic function (Looney et al., 2004;
Sanz et al., 2007; Hauser et al., 2008;
McFarland, 2008). Although a detailed
discussion of the multiple mechanisms
that could account for this process is
outside the scope of this review, suffice
it to say here that a main corollary
of this model would be that effective
B-cell tolerance should preclude
the generation of effector B cells
with pathogenic, antibody-independent
function as we and others have pro-
posed (Harris et al., 2000; Wei et al.,
2007; Sanz et al., 2008) (Figure 2).
Whether such effector cells share a
common precursor with antibody-
secreting cells or are the progeny of
a different precursor population also
remains to be elucidated.
B cells as agents of immunological
tolerance
B cells are powerful mediators of
antigen presentation, cytokine, and
chemokine production and multiple
other antibody-independent functions
(summarized in Table 2) (Martin and
Chan, 2006; Sanz et al., 2007).
Through these functions, B cells exert
critical influence over lymphoid archi-
tecture, T-cell and dendritic cell reg-
ulation, and possibly (although this
aspect is less well understood) over
the regulation of other B-cell subsets.
Through a poorly understood balance
between these functions, B cells can
have either protective or pathogenic
roles in autoimmunity (Figure 3). Such
Janus-like behavior of B cells in auto-
immunity is illustrated by their duplici-
tous influence over T regulatory cells.
On the one hand, B cells mediate or
enable autoinflammatory disease by
inhibiting Tregs at least in some cases
after being recruited by effector CD4 T
cells (Olson et al., 2004; Yu et al.,
2006). On the other hand, the com-
bined evidence from several studies
strongly suggests the existence of
protective regulatory B cells capable
of preventing or suppressing autoim-
munity. This beneficial effect can be
mediated either by the production of
cytokines such as IL-10 or transforming
growth factor-b, the induction of T-cell
Table 2. Antibody-independent functions of B cells (Sanz et al., 2007)
Lymphotoxin dependent Formation of the T-cell zone
Formation of the marginal zone
Maturation of FDC networks
Homeostasis of dendritic cells
Recruitment of germinal center DC cells
Lymphoid neogenesis
Lymphotoxin independent
T-cell functions Priming/expansion of naive CD4 cells
Priming of naive CD8 cells
T-cell anergy tolerance
Activation of autoreactive CD4/CD8 cells
Promotion of Th2 differentiation
Induction of Th1 differentiation
Inhibition of Th1 and Th17 cells (TLR mediated)
(Lampropoulou et al., 2008)
Recruitment of FTH (follicular helper) T cells
Inhibition of T regulatory cells
Expansion of T regulatory cells
Dendritic cells functions Maturation and migration of DCs
Activation of DCs
Inhibition of DC-induced T-cell immunity
Attenuation of IL-12-induced Th1 differentiation
Cytokine production IL-1, IL-4, IL-6, IL-8, IL-7, G-CSF, GM-CSF, IL-10 IL-12,
TNFa, LTa, TGF, BMP-6/7, VEGF-A
Chemokine production MIP-1a, MIP-1b, IL-16, CXCL13 (Takemura et al., 2001)
Lymphangiogenesis and
lymph node expansion
BMP9, bone morphogenic protein 9; CSF, cerebrospinal fluid; DC, dendritic cell; FDC, follicular
dendritic cells; LTa, lymphotoxin a; MIP-1a, macrophage inflammatory protein-1a; TGFb,
transforming growth factor-b; TLR, toll-like receptor; TNF-a, tumor necrosis factor-a.
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anergy and/or by the ability of at least
some B-cell populations to induce Treg
cells (Mizoguchi et al., 2002; Mauri
et al., 2003; Wei et al., 2005; Chen and
Jensen, 2007; Reichardt et al., 2007;
Zhong et al., 2007). Of significant
interest, B cells may also be essential
for the induction of cardiac allograft
tolerance that can be induced by anti-
CD45RB antibodies (Deng et al.,
2007). In this case, it has been postu-
lated that activated B cells might
enhance the responsiveness of respon-
der T cells to Tregs.
These tantalizing observations raise a
number of important questions regard-
ing the nature, timing, and mechanism
of action of protective, regulatory B
cells. Indeed, different studies suggest
that the disease suppressing activity of B
cells may only occur in specific situa-
tions depending on either: (1) their
absolute numbers, (2) their relative
frequency and dominance over patho-
genic B cells, and/or (3) a gain-of-
inhibitory function that was previously
absent. Thus, in collagen-induced ar-
thritis models a protective population of
IL-10 producing B cells with a pheno-
type of transitional 2/MZ precursors (T2-
MZP) is capable of inducing disease
remission upon adaptive transfer even if
the same phenotypical endogenous
population is incapable of preventing
disease in collagen-induced arthritis-
immunized animals (Evans et al.,
2007). In this model, the adoptive
transfer of T2-MZP B cells at an early
stage of disease renders autoreactive T
cells unresponsive to CII and unable to
produce cytokines essential for the
pathogenesis of arthritis. T2-MZP B-cell
transfer significantly suppressed the CII-
specific IgG response and induced a
switch away from a ‘‘pathogenic’’ Th1
IgG2a toward a more ‘‘protective Th2-
like’’ IgG1 response. Of great interest,
these effects were mediated by inhibi-
tion of CII-specific IFNg-producing Th1
cytokines. The data indicate that the
suppression induced by T2-MZP B cells
is, at least in part, specific for the
antigen to which these B cells had been
exposed. This would suggest that anti-
gen-specific autoreactive B cells gained
a protective ability upon transfer that
they did not initially have. Similarly, a
gain-of-inhibitory function can also
be gleaned from a report published
during the writing of this manuscript
showing that TLR-activated B cells
can suppress Th1 and Th17 responses
through the production of IL-10
and induce clinical remission in experi-
mental autoimmune encephalomyelitis
(Lampropoulou et al., 2008).
The significance of these results is
enhanced by elegant results in non-
obese diabetic mice and by our own
observations in human SLE. Thus, Hu
et al. (2007)have shown that upon B-
cell depletion and reconstitution, the
expanding B cells (with a predomi-
nance of transitional B cells) mediate
dominant suppression of diabetogenic
T cells. Similarly, our own data in SLE
patients treated with rituximab-induced
B-cell depletion therapy have shown a
strong correlation between long-term
clinical responses and a B-cell recon-
stitution profile dominated for more
than 2 years by large numbers of
transitional B cells and a scarcity of
memory B cells (Anolik et al., 2007a).
It should be noted however that the
actual mechanism of action of these
protective B cells remains to be eluci-
dated. Thus, in accord with the ob-
servations of Merrell et al. (2006)
previously discussed, it is likely that
phenotypically T2-MZP cells would
include anergic T3 B cells with high
T-cell tolerogenic potential due to lack
of expression of CD86 and other co-
stimulatory molecules (Eynon and
Parker, 1992). As we have previously
discussed in our rituximab studies in
SLE, this mechanism could contribute
to explain the beneficial effect of
repopulating B cells (Anolik et al.,
2007a). Of particular interest, our un-
published observations strongly indi-
cate that cells with a T3 phenotype are
overrepresented in the repopulating
repertoire of rituximab-treated patients
with good clinical and immunological
responses (Anolik et al., Submitted). It
is also important to bear in mind that
IL-10 itself might contribute to the
downregulation of B7 co-stimulatory
molecules perhaps providing a link
between the two proposed mechanisms
(Ding et al., 1993).
Combined, the available evidence
in mice and humans strongly indicates
that a disturbed balance between pro-
tective and pathogenic B-cell activity
may strongly contribute to active auto-
immune disease and that a favorable
balance appears to be restored by
B-cell depletion therapy in patients
with good clinical response (Figure 4).
Of significant interest, this model is
also supported by the observation that
the ability of B cells to produce anti-
inflammatory IL-10 is restored in pa-
tients with multiple sclerosis after
treatment with rituximab (Duddy
et al., 2007). In these studies, the IL-
10 producing cells were characterized
as naive on the basis of their expression
of IgD and CD27. It should be noted
however that, as shown by our labora-
tory, these markers would not
Potective B-
cell functions
Transitional-
naÏve B cells
IL-10, TGF
Pathogenic B-
cell functions
Memory B cells
IL-12p40
IFN, TNF
Protective B-
cell functions
IL-10, TGF
Transitional
naÏve B cells
Pathogenic B-
cell functions
Memory B cells
IL-12p40
IFN, TNF
Disease prevention
and/or remission
Treatment failure and/or
disease exacerbation 
Figure 4. Functional balance between protective and pathogenic B-cell functions. This figure is
predicated on the notion that proinflammatory pathogenic functions may be concentrated on memory
B cells, whereas transitional and possibly naive B cells might provide protection at least in part by the
secretion of cytokines such as IL-10 and transforming growth factor-b. Consequently, the relative balance
achieved between these two opposing populations/activities would determine disease course and
response to treatment.
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discriminate between naive and transi-
tional cells and therefore, the actual
phenotype of the protective B cells
remains open to question (Anolik et al.,
2007b; Sanz et al., 2008).
These important observations and
the models proposed to explain them
raise more questions than they answer,
including the nature of the regulatory B
cells, the mechanisms whereby they
may gain protective function, and the
triggers of such gain-of-function. It
seems likely however that the function
of a given B-cell subset will be altered
by the cytokine milieu of the autoim-
mune disease in question. Consistent
with this concept is the observation that
IL-10 may have proinflammatory
effects when primed by type I IFN
(Sharif et al., 2004). This scenario may
help explain the seemingly paradoxical
pathogenic role of B cell-produced
IL-10 in SLE (Llorente et al., 1995,
2000). It can also account for our
observation that a dominance of transi-
tional B cells is not necessarily protec-
tive in patients with SLE (Anolik et al.,
manuscript in preparation).
Finally, it also remains to be deter-
mined whether the transitional/naive-
dominated B-cell environment that can
be induced by B-cell depletion can
restore B- and T-cell tolerance. Our
own results however strongly indicate
that this is indeed the case as we have
found that physiological censoring of
autoreactive 9G4 B cells is restored in
SLE patients with long-term responses
whose peripheral B-cell compartment
is dominated by transitional cells dur-
ing reconstitution (Anolik et al., 2006).
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